Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARA 290 in active rheumatoid arthritis
NL-OMON22511Phase 2Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cibinetide in rheumatoid arthritis (RA) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Disease activity, Functional ability and 1 more. Planned start Jan 2011; status: not yet recruiting.
02
Drugs
cibinetide
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON22511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22511.